Gene Panel Predicts Damage in Donated Kidneys
By LabMedica International staff writers Posted on 04 Aug 2016 |
Image: The Aperio Scanscope CS whole slide scanner system (Photo courtesy of Leica).
Kidney transplantation is a life-extending procedure and a panel of genes has been identified that can help predict whether a transplanted kidney will later develop fibrosis, an injury which can cause the organ to fail.
Chronic allograft damage, or interstitial fibrosis and tubular atrophy of unknown cause, is the major cause of allograft loss in the first year after transplantation. Clinical and histological events associated with interstitial fibrosis and tubular atrophy are poorly predictive of allograft loss, making it difficult to identify allografts that could benefit from early interventions to prevent progression of fibrosis.
A multicenter team of scientists led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) prospectively collected biopsies from 204 renal allograft recipients with stable renal function three months after transplantation. They used microarray analysis to investigate gene expression in 159 of these tissue samples. Their aim was to genes that correlated with the Chronic Allograft Damage Index (CADI) score at 12 months, but not fibrosis at the time of the biopsy. The CADI score is a measure of the level of fibrosis in the transplanted kidney.
Two tissue cores were taken from each of the three-month and one year protocol renal biopsies of the Genomics of Chronic Allograft Rejection (GoCAR) cohort. One core was processed for histology and the other core was processed for messenger ribonucleic acid (mRNA). Immunohistochemistry was done on an automated stainer on paraffin sections stained with a rabbit polyclonal antibody (American Research Products, Inc, Waltham, MA, USA). All slides were scanned with an Aperio CS whole slide scanner (Leica, Wetzlar, Germany) and high-resolution digital images and archived in an image database. Total RNA was extracted from percutaneous graft biopsy samples, processed onto gene chips and scanned using GeneChip Scanner 7G (Affymetrix Inc, Santa Clara, CA, USA).
The investigators identified a set of 13 genes that was independently predictive for the development of fibrosis at one year. The routine pathological variables were unable to identify which histologically normal allografts would progress to fibrosis whereas the predictive gene set accurately discriminated between transplants at high and low risk of progression. The rate of correlation of the identified gene set with damage was greater than the clinico-pathological variables currently used in practice to identify kidney transplant recipients at risk of allograft damage and loss.
Barbara Murphy, MD, the study leader, said, “By helping us better understand the causes of damage to transplanted kidneys; this study has the potential to change how we monitor and manage all renal transplant patients. The study offers the potential to identify renal transplant recipients at risk for a loss of the new organ prior to the development of irreversible damage. This would mean that doctors might eventually have the opportunity to change the therapeutic treatment approach in order to prevent fibrosis from progressing at all.” The study was published on July 22, 2016, in the journal The Lancet.
Related Links:
Icahn School of Medicine at Mount Sinai
American Research Products
Leica
Affymetrix
Chronic allograft damage, or interstitial fibrosis and tubular atrophy of unknown cause, is the major cause of allograft loss in the first year after transplantation. Clinical and histological events associated with interstitial fibrosis and tubular atrophy are poorly predictive of allograft loss, making it difficult to identify allografts that could benefit from early interventions to prevent progression of fibrosis.
A multicenter team of scientists led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) prospectively collected biopsies from 204 renal allograft recipients with stable renal function three months after transplantation. They used microarray analysis to investigate gene expression in 159 of these tissue samples. Their aim was to genes that correlated with the Chronic Allograft Damage Index (CADI) score at 12 months, but not fibrosis at the time of the biopsy. The CADI score is a measure of the level of fibrosis in the transplanted kidney.
Two tissue cores were taken from each of the three-month and one year protocol renal biopsies of the Genomics of Chronic Allograft Rejection (GoCAR) cohort. One core was processed for histology and the other core was processed for messenger ribonucleic acid (mRNA). Immunohistochemistry was done on an automated stainer on paraffin sections stained with a rabbit polyclonal antibody (American Research Products, Inc, Waltham, MA, USA). All slides were scanned with an Aperio CS whole slide scanner (Leica, Wetzlar, Germany) and high-resolution digital images and archived in an image database. Total RNA was extracted from percutaneous graft biopsy samples, processed onto gene chips and scanned using GeneChip Scanner 7G (Affymetrix Inc, Santa Clara, CA, USA).
The investigators identified a set of 13 genes that was independently predictive for the development of fibrosis at one year. The routine pathological variables were unable to identify which histologically normal allografts would progress to fibrosis whereas the predictive gene set accurately discriminated between transplants at high and low risk of progression. The rate of correlation of the identified gene set with damage was greater than the clinico-pathological variables currently used in practice to identify kidney transplant recipients at risk of allograft damage and loss.
Barbara Murphy, MD, the study leader, said, “By helping us better understand the causes of damage to transplanted kidneys; this study has the potential to change how we monitor and manage all renal transplant patients. The study offers the potential to identify renal transplant recipients at risk for a loss of the new organ prior to the development of irreversible damage. This would mean that doctors might eventually have the opportunity to change the therapeutic treatment approach in order to prevent fibrosis from progressing at all.” The study was published on July 22, 2016, in the journal The Lancet.
Related Links:
Icahn School of Medicine at Mount Sinai
American Research Products
Leica
Affymetrix
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans